8:07 am Merrimack Pharma: Preclinical study results of Merrimack’s MM-141 published in Molecular Cancer Therapeutics; MM-141, a novel bispecific tetravalent antibody, blocks redundant cancer survival pathways
View todays social media effects on MACK
View the latest stocks trending across Twitter. Click to view dashboard
See who Merrimack is hiring next, click here to view
